235 related articles for article (PubMed ID: 24841553)
1. Context-dependent function of the deubiquitinating enzyme USP9X in pancreatic ductal adenocarcinoma.
Cox JL; Wilder PJ; Wuebben EL; Ouellette MM; Hollingsworth MA; Rizzino A
Cancer Biol Ther; 2014 Aug; 15(8):1042-52. PubMed ID: 24841553
[TBL] [Abstract][Full Text] [Related]
2. Usp9x Promotes Survival in Human Pancreatic Cancer and Its Inhibition Suppresses Pancreatic Ductal Adenocarcinoma In Vivo Tumor Growth.
Pal A; Dziubinski M; Di Magliano MP; Simeone DM; Owens S; Thomas D; Peterson L; Potu H; Talpaz M; Donato NJ
Neoplasia; 2018 Feb; 20(2):152-164. PubMed ID: 29248719
[TBL] [Abstract][Full Text] [Related]
3. Deubiquitinase USP9X promotes cell migration, invasion and inhibits apoptosis of human pancreatic cancer.
Liu L; Yao D; Zhang P; Ding W; Zhang X; Zhang C; Gong S; Zhang Y; Wang J; Sun T; Ren Z
Oncol Rep; 2017 Dec; 38(6):3531-3537. PubMed ID: 29130109
[TBL] [Abstract][Full Text] [Related]
4. The USP22 promotes the growth of cancer cells through the DYRK1A in pancreatic ductal adenocarcinoma.
Bai Z; Du Y; Cong L; Cheng Y
Gene; 2020 Oct; 758():144960. PubMed ID: 32687947
[TBL] [Abstract][Full Text] [Related]
5. The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma.
Pérez-Mancera PA; Rust AG; van der Weyden L; Kristiansen G; Li A; Sarver AL; Silverstein KA; Grützmann R; Aust D; Rümmele P; Knösel T; Herd C; Stemple DL; Kettleborough R; Brosnan JA; Li A; Morgan R; Knight S; Yu J; Stegeman S; Collier LS; ten Hoeve JJ; de Ridder J; Klein AP; Goggins M; Hruban RH; Chang DK; Biankin AV; Grimmond SM; ; Wessels LF; Wood SA; Iacobuzio-Donahue CA; Pilarsky C; Largaespada DA; Adams DJ; Tuveson DA
Nature; 2012 Apr; 486(7402):266-70. PubMed ID: 22699621
[TBL] [Abstract][Full Text] [Related]
6. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
[TBL] [Abstract][Full Text] [Related]
7. USP9X inhibition improves gemcitabine sensitivity in pancreatic cancer by inhibiting autophagy.
Ma T; Chen W; Zhi X; Liu H; Zhou Y; Chen BW; Hu L; Shen J; Zheng X; Zhang S; Zhang B; Li H; Liang T
Cancer Lett; 2018 Nov; 436():129-138. PubMed ID: 30118840
[TBL] [Abstract][Full Text] [Related]
8. WP1130 increases doxorubicin sensitivity in hepatocellular carcinoma cells through usp9x-dependent p53 degradation.
Liu H; Chen W; Liang C; Chen BW; Zhi X; Zhang S; Zheng X; Bai X; Liang T
Cancer Lett; 2015 Jun; 361(2):218-25. PubMed ID: 25749422
[TBL] [Abstract][Full Text] [Related]
9. Deubiquitinase ubiquitin-specific protease 9X regulates the stability and function of E3 ubiquitin ligase ring finger protein 115 in breast cancer cells.
Lu Q; Lu D; Shao ZM; Li DQ
Cancer Sci; 2019 Apr; 110(4):1268-1278. PubMed ID: 30689267
[TBL] [Abstract][Full Text] [Related]
10. Ubiquitin-specific protease 14 (USP14) promotes proliferation and metastasis in pancreatic ductal adenocarcinoma.
Hang C; Gong C; Fang Y; Chen L; Zhu J
J Mol Histol; 2021 Apr; 52(2):187-196. PubMed ID: 33394290
[TBL] [Abstract][Full Text] [Related]
11. USP9X mediates an acute adaptive response to MAPK suppression in pancreatic cancer but creates multiple actionable therapeutic vulnerabilities.
Perurena N; Lock R; Davis RA; Raghavan S; Pilla NF; Ng R; Loi P; Guild CJ; Miller AL; Sicinska E; Cleary JM; Rubinson DA; Wolpin BM; Gray NS; Santagata S; Hahn WC; Morton JP; Sansom OJ; Aguirre AJ; Cichowski K
Cell Rep Med; 2023 Apr; 4(4):101007. PubMed ID: 37030295
[TBL] [Abstract][Full Text] [Related]
12. Loss of heterozygosity for Kras
Ma Y; Li Y; Ling S; Li X; Kong B; Hu M; Huang P
Biochem Biophys Res Commun; 2020 Jun; 526(4):880-888. PubMed ID: 32279996
[TBL] [Abstract][Full Text] [Related]
13. Deubiquitinase inhibitor degrasyn suppresses metastasis by targeting USP5-WT1-E-cadherin signalling pathway in pancreatic ductal adenocarcinoma.
Li J; Li H; Zhu W; Zhou B; Ying J; Wu J; Zhang H; Sun H; Gao S
J Cell Mol Med; 2020 Jan; 24(2):1370-1382. PubMed ID: 31845546
[TBL] [Abstract][Full Text] [Related]
14. Delivery of miR-212 by chimeric peptide-condensed supramolecular nanoparticles enhances the sensitivity of pancreatic ductal adenocarcinoma to doxorubicin.
Chen W; Zhou Y; Zhi X; Ma T; Liu H; Chen BW; Zheng X; Xie S; Zhao B; Feng X; Dang X; Liang T
Biomaterials; 2019 Feb; 192():590-600. PubMed ID: 30553134
[TBL] [Abstract][Full Text] [Related]
15. SOX2 functions as a molecular rheostat to control the growth, tumorigenicity and drug responses of pancreatic ductal adenocarcinoma cells.
Wuebben EL; Wilder PJ; Cox JL; Grunkemeyer JA; Caffrey T; Hollingsworth MA; Rizzino A
Oncotarget; 2016 Jun; 7(23):34890-906. PubMed ID: 27145457
[TBL] [Abstract][Full Text] [Related]
16. USP9X stabilizes BRCA1 and confers resistance to DNA-damaging agents in human cancer cells.
Lu Q; Zhang FL; Lu DY; Shao ZM; Li DQ
Cancer Med; 2019 Nov; 8(15):6730-6740. PubMed ID: 31512408
[TBL] [Abstract][Full Text] [Related]
17. Loss of the transcriptional repressor TGIF1 results in enhanced Kras-driven development of pancreatic cancer.
Weng CC; Hsieh MJ; Wu CC; Lin YC; Shan YS; Hung WC; Chen LT; Cheng KH
Mol Cancer; 2019 May; 18(1):96. PubMed ID: 31109321
[TBL] [Abstract][Full Text] [Related]
18. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
[TBL] [Abstract][Full Text] [Related]
19. HnRNPK/miR-223/FBXW7 feedback cascade promotes pancreatic cancer cell growth and invasion.
He D; Huang C; Zhou Q; Liu D; Xiong L; Xiang H; Ma G; Zhang Z
Oncotarget; 2017 Mar; 8(12):20165-20178. PubMed ID: 28423622
[TBL] [Abstract][Full Text] [Related]
20. β2-adrenergic receptor signaling promotes pancreatic ductal adenocarcinoma (PDAC) progression through facilitating PCBP2-dependent c-myc expression.
Wan C; Gong C; Zhang H; Hua L; Li X; Chen X; Chen Y; Ding X; He S; Cao W; Wang Y; Fan S; Xiao Y; Zhou G; Shen A
Cancer Lett; 2016 Apr; 373(1):67-76. PubMed ID: 26803058
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
